Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 3/20 | 0.44 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148548 | 0.89 | GLRA1 (0.46) | GLRA1ERN1CCNB2CDK1CDK4 | |
| SCHEMBL21822963 | 0.88 | ERN1 (0.43) | ERN1CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL2267469 | 0.82 | ERN1 (0.43) | GLRA1ERN1CCNB2CDK1CDK4 | |
| SCHEMBL31056124 | 0.81 | MAPT (0.50) | ERN1CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL12368068 | 0.80 | HTR1A (0.40) | GLRA1ERN1CCNB2CDK1CDK4 | |
| SCHEMBL24983810 | 0.80 | MAPT (0.51) | ERN1CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL12556342 | 0.80 | LIPE (0.55) | GLRA1MAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL17833744 | 0.79 | CHRNA7 (0.47) | GLRA1MAPTL3MBTL1MAPK1TDP1 | |
| SCHEMBL2908502 | 0.79 | FFAR4 (0.49) | ERN1CCNB2CDK1CDK4CCNB1 | |
| SCHEMBL4566984 | 0.78 | MCL1 (0.54) | GLRA1MAPTL3MBTL1TDP1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-12-24 | — | — | US | disclosed |
| US-9120745-B2 | Triazole compounds that modualte HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8993608-B2 | Method for inhibiting topoisomerase II | SYNTA PHARMACEUTICALS CORP. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8927548-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140296186-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2014-10-02 | — | — | US | disclosed |
| US-8742133-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20140141511-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2012-05-17 | — | — | US | disclosed |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-08-11 | — | — | US | disclosed |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, CDC37 | GLRA1 3514/4885ERN1 1083/4885CCNB2 1093/4885 |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885ERN1 1808/4885CCNB2 998/4885 |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | GLRA1 4278/4885ERN1 2486/4885CCNB2 334/4885 |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885ERN1 1808/4885CCNB2 998/4885 |
| US-20140141511-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | GLRA1 4211/4885ERN1 4113/4885CCNB2 4323/4885 |
| US-20140296186-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885ERN1 1808/4885CCNB2 998/4885 |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 3902/4885ERN1 1808/4885CCNB2 998/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | GLRA1 4278/4885ERN1 2486/4885CCNB2 334/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | GLRA1 4211/4885ERN1 4113/4885CCNB2 4323/4885 |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | HSP90AB1, HSP90B1, HSP90AA1 | GLRA1 4595/4885ERN1 2445/4885CCNB2 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.